Glenmark stock gets US launch of generic Inlyta treatment
Published on 11/18/2026 at 00:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGlenmark expands its US portfolio
- The company launched an authorized generic version of Pfizer's Inlyta for advanced renal cell carcinoma.
- IQVIA recorded USD 538.4 million in US sales for the reference product in the 12 months through September 2026.
- The launch follows a sharp decline in Glenmark's September-quarter reported revenue and net profit.
Glenmark Pharmaceuticals launched Axitinib Tablets in the United States on November 16, adding an authorized generic version of Pfizer's Inlyta to its portfolio. The launch covers 1 mg and 5 mg strengths and targets advanced renal cell carcinoma, a form of kidney cancer. Economic Times reported the announcement on November 17.
IQVIA data cited in the announcement put US sales of the reference product at USD 538.4 million for the 12 months ended September 2026. That figure refers to Pfizer's Inlyta and is not Glenmark revenue from the new launch. The product expands Glenmark's presence in the US generic-drug market, while the commercial contribution will depend on pricing, competition and prescription uptake.
Launch follows weak quarterly comparison
The launch comes after Glenmark reported a 56.7 percent year-over-year decline in consolidated net profit to INR 264 crore for the quarter ended September 2026. Revenue from operations fell 29.8 percent to INR 4,247.3 crore, while EBITDA declined 63.4 percent to INR 864 crore, according to IANS. The company said its core North American business grew about 31 percent excluding deferred out-licensing income related to ISB 2001.
Glenmark's India formulations business generated INR 1,327.4 crore in the quarter, while North America revenue reached INR 1,208.9 crore. The figures show why additional US launches matter for the company's regional mix, even as reported comparisons remain affected by prior-period licensing income.
Glenmark's medicines business
Glenmark Pharmaceuticals develops and sells medicines, including generic products in the United States. Its reported operations span India formulations, North America, Europe and emerging markets. The company is using additional US launches to broaden its pharmaceutical portfolio.
Glenmark Pharmaceuticals at a glance
- Company: Glenmark Pharmaceuticals
- Event date: November 16, 2026
- US product: Axitinib Tablets, authorized generic of Pfizer's Inlyta
- Strengths: 1 mg and 5 mg
- Reference-product US sales: USD 538.4 million in the 12 months ended September 2026
- Indication: Advanced renal cell carcinoma
Indian equities provide the broader market setting for Glenmark; see the Nifty 50 market environment.
